Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer.

Autor: van de Weerd S; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Torang A; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van den Berg I; Department of Surgery, Erasmus MC, University Medical center Rotterdam, Rotterdam, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Lammers V; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van den Bergh S; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Brouwer N; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Nagtegaal ID; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Vink GR; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., van der Baan FH; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., van Krieken H; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Koster J; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands., Ijzermans JN; Department of Surgery, Erasmus MC, University Medical center Rotterdam, Rotterdam, The Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Medema JP; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2025 Jan 15; Vol. 156 (2), pp. 456-466. Date of Electronic Publication: 2024 Aug 08.
DOI: 10.1002/ijc.35120
Abstrakt: The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p < .01, HR 0.19; p < .01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p = .51). CMS subtyping in this non-randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy.
(© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
Databáze: MEDLINE
Externí odkaz: